• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

代谢型谷氨酸受体激动剂和拮抗剂的潜在精神科应用。

Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists.

机构信息

Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA.

出版信息

CNS Drugs. 2010 Aug;24(8):669-93. doi: 10.2165/11533230-000000000-00000.

DOI:10.2165/11533230-000000000-00000
PMID:20658799
Abstract

Drugs acting at metabotropic glutamate receptors (mGluRs) are among the most promising agents under development for the treatment of psychiatric disorders. The research in this area is at a relatively early stage, as there are no drugs acting at mGluRs that have been approved for the treatment of any psychiatric disorder. However, in the areas of schizophrenia, anxiety disorders and mood disorders, research conducted in animal models appears to translate well into efficacy in human laboratory-based models of psychopathology and in preliminary clinical trials. Further, the genes coding for mGluRs are implicated in the risk for a growing number of psychiatric disorders. This review highlights the best studied mGluR strategies for psychiatry, based on human molecular genetics, studies in animal models and preliminary clinical trials. It describes the potential value of mGluR2 and mGluR5 agonists and positive allosteric modulators for the treatment of schizophrenia. It also reviews evidence that group II mGluR agonists and positive allosteric modulators as well as group I mGluR antagonists might also treat anxiety disorders and some forms of depression, while mGluR2 and group I mGluR antagonists (particularly mGluR5 antagonists) might have antidepressant properties. This review also links growing insights into the role of glutamate in the pathophysiology of these disorders to hypothesized mGluR-related treatment mechanisms.

摘要

作用于代谢型谷氨酸受体(mGluRs)的药物是目前开发用于治疗精神疾病的最有前途的药物之一。该领域的研究尚处于早期阶段,因为目前尚无作用于 mGluRs 的药物被批准用于治疗任何精神疾病。然而,在精神分裂症、焦虑症和心境障碍等领域,在动物模型中进行的研究似乎在精神病理学的人类实验室模型和初步临床试验中得到了很好的转化。此外,编码 mGluR 的基因与越来越多的精神疾病的风险有关。本综述根据人类分子遗传学、动物模型研究和初步临床试验,重点介绍了精神药理学中研究最深入的 mGluR 策略。它描述了 mGluR2 和 mGluR5 激动剂和正变构调节剂在治疗精神分裂症方面的潜在价值。它还回顾了证据表明,II 组 mGluR 激动剂和正变构调节剂以及 I 组 mGluR 拮抗剂也可能治疗焦虑症和某些形式的抑郁症,而 mGluR2 和 I 组 mGluR 拮抗剂(特别是 mGluR5 拮抗剂)可能具有抗抑郁作用。该综述还将对这些疾病病理生理学中谷氨酸作用的新认识与假设的 mGluR 相关治疗机制联系起来。

相似文献

1
Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists.代谢型谷氨酸受体激动剂和拮抗剂的潜在精神科应用。
CNS Drugs. 2010 Aug;24(8):669-93. doi: 10.2165/11533230-000000000-00000.
2
Targeting of metabotropic glutamate receptors for the treatment of schizophrenia.针对代谢型谷氨酸受体治疗精神分裂症。
Curr Pharm Des. 2011;17(2):94-102. doi: 10.2174/138161211795049570.
3
Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity.发现代谢型谷氨酸受体亚型 5 的新型别构调节剂,揭示了其在抗焦虑和抗精神病活性的大鼠行为模型中的化学和功能多样性及体内活性。
Mol Pharmacol. 2010 Dec;78(6):1105-23. doi: 10.1124/mol.110.067207. Epub 2010 Oct 5.
4
Recent advances in positive allosteric modulators of metabotropic glutamate receptors.代谢型谷氨酸受体正变构调节剂的最新进展。
Curr Opin Drug Discov Devel. 2005 Jul;8(4):449-57.
5
Clinical investigations of compounds targeting metabotropic glutamate receptors.针对代谢型谷氨酸受体的化合物的临床研究。
Pharmacol Biochem Behav. 2022 Sep;219:173446. doi: 10.1016/j.pbb.2022.173446. Epub 2022 Aug 17.
6
Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice.联苯茚满二酮A,一种亲代谢型谷氨酸受体亚型2的正变构调节剂,在小鼠中具有抗精神病样和抗焦虑样作用。
J Pharmacol Exp Ther. 2006 Jul;318(1):173-85. doi: 10.1124/jpet.106.102046. Epub 2006 Apr 11.
7
Metabotropic glutamate mGlu1 receptor stimulation and blockade: therapeutic opportunities in psychiatric illness.代谢型谷氨酸 mGlu1 受体刺激和阻断:精神疾病的治疗机会。
Eur J Pharmacol. 2010 Aug 10;639(1-3):2-16. doi: 10.1016/j.ejphar.2009.12.043. Epub 2010 Apr 2.
8
Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.谷氨酸调节剂作为精神分裂症和情感障碍的潜在治疗药物。
Eur Arch Psychiatry Clin Neurosci. 2013 Aug;263(5):367-77. doi: 10.1007/s00406-013-0399-y. Epub 2013 Mar 1.
9
Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders.靶向代谢型谷氨酸受体治疗抑郁症和其他与应激相关的障碍。
Neuropharmacology. 2021 Sep 15;196:108687. doi: 10.1016/j.neuropharm.2021.108687. Epub 2021 Jun 25.
10
Positive and negative modulation of circadian activity rhythms by mGluR5 and mGluR2/3 metabotropic glutamate receptors.代谢型谷氨酸受体 5 和 2/3 对昼夜活动节律的正、负调制。
Neuropharmacology. 2011 Feb-Mar;60(2-3):209-15. doi: 10.1016/j.neuropharm.2010.08.022. Epub 2010 Sep 8.

引用本文的文献

1
Metabotropic Glutamate Receptor 5 as a Potential Biomarker of the Intersection of Trauma and Cannabis Use.代谢型谷氨酸受体 5 作为创伤和大麻使用交叉点的潜在生物标志物。
Int J Neuropsychopharmacol. 2024 Oct 1;27(10). doi: 10.1093/ijnp/pyae044.
2
Magnesium (Mg): Essential Mineral for Neuronal Health: From Cellular Biochemistry to Cognitive Health and Behavior Regulation.镁(Mg):神经元健康的必需矿物质:从细胞生物化学到认知健康和行为调节。
Curr Pharm Des. 2024;30(39):3074-3107. doi: 10.2174/0113816128321466240816075041.
3
Protein Kinase C (PKC) in Neurological Health: Implications for Alzheimer's Disease and Chronic Alcohol Consumption.

本文引用的文献

1
Involvement of the metabotropic glutamate receptor mGluR5 in NMDA receptor-dependent, learning-facilitated long-term depression in CA1 synapses.代谢型谷氨酸受体 mGluR5 参与 NMDA 受体依赖性、学习促进的 CA1 突触长时程抑郁。
Cereb Cortex. 2011 Mar;21(3):501-9. doi: 10.1093/cercor/bhq093. Epub 2010 Jun 4.
2
De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia.在经确定患有精神分裂症的患者中,突触支架蛋白 SHANK3 基因的从头突变。
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7863-8. doi: 10.1073/pnas.0906232107. Epub 2010 Apr 12.
3
Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia.
蛋白激酶C(PKC)在神经健康中的作用:对阿尔茨海默病和长期饮酒的影响
Brain Sci. 2024 May 29;14(6):554. doi: 10.3390/brainsci14060554.
4
Loss of mGlu receptors in somatostatin-expressing neurons alters negative emotional states.生长抑素表达神经元中 mGlu 受体的缺失改变了负性情绪状态。
Mol Psychiatry. 2024 Sep;29(9):2774-2786. doi: 10.1038/s41380-024-02541-5. Epub 2024 Apr 4.
5
The role of mGluR5 on the therapeutic effects of ketamine in Wistar rats.mGluR5 在氯胺酮治疗 Wistar 大鼠中的作用。
Psychopharmacology (Berl). 2024 Jul;241(7):1399-1415. doi: 10.1007/s00213-024-06571-3. Epub 2024 Mar 9.
6
Preliminary Study of White Matter Abnormalities and Associations With the Metabotropic Glutamate Receptor 5 to Distinguish Bipolar and Major Depressive Disorders.白质异常与代谢型谷氨酸受体5的关联用于鉴别双相情感障碍和重度抑郁症的初步研究
Chronic Stress (Thousand Oaks). 2024 Jan 17;8:24705470231225320. doi: 10.1177/24705470231225320. eCollection 2024 Jan-Dec.
7
Biological embedding of early trauma: the role of higher prefrontal synaptic strength.早期创伤的生物学嵌入:前额叶皮质更高的突触强度的作用。
Eur J Psychotraumatol. 2023;14(2):2246338. doi: 10.1080/20008066.2023.2246338.
8
Discovery of MK-8768, a Potent and Selective mGluR2 Negative Allosteric Modulator.强效选择性代谢型谷氨酸受体2负变构调节剂MK-8768的发现
ACS Med Chem Lett. 2023 Jul 12;14(8):1088-1094. doi: 10.1021/acsmedchemlett.3c00210. eCollection 2023 Aug 10.
9
Discovery of [C]MK-8056: A Selective PET Imaging Agent for the Study of mGluR Negative Allosteric Modulators.[C]MK-8056的发现:一种用于研究代谢型谷氨酸受体负变构调节剂的选择性正电子发射断层扫描(PET)成像剂。
ACS Med Chem Lett. 2023 Jun 13;14(7):986-992. doi: 10.1021/acsmedchemlett.3c00175. eCollection 2023 Jul 13.
10
Differences in Quantification of the Metabotropic Glutamate Receptor 5 Across Bipolar Disorder and Major Depressive Disorder.双相障碍和重度抑郁症中代谢型谷氨酸受体 5 定量的差异。
Biol Psychiatry. 2023 Jun 15;93(12):1099-1107. doi: 10.1016/j.biopsych.2022.10.018. Epub 2022 Nov 8.
神经可塑性作为焦虑障碍、心境障碍和精神分裂症药物治疗的靶点。
Drug Discov Today. 2009 Jul;14(13-14):690-7. doi: 10.1016/j.drudis.2009.05.002. Epub 2009 May 19.
4
Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia.代谢型谷氨酸受体的激活作为治疗精神分裂症的一种新方法。
Trends Pharmacol Sci. 2009 Jan;30(1):25-31. doi: 10.1016/j.tips.2008.10.006. Epub 2008 Dec 6.
5
Mental disorders as risk factors for later substance dependence: estimates of optimal prevention and treatment benefits.精神障碍作为后期物质依赖的风险因素:最佳预防和治疗效益的评估
Psychol Med. 2009 Aug;39(8):1365-77. doi: 10.1017/S0033291708004510. Epub 2008 Dec 2.
6
Orbitofrontal cortex neurons as a common target for classic and glutamatergic antipsychotic drugs.眶额皮质神经元作为经典和谷氨酸能抗精神病药物的共同靶点。
Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):18041-6. doi: 10.1073/pnas.0806669105. Epub 2008 Nov 12.
7
Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome.重度抑郁症门诊患者中焦虑与物质使用障碍共病:临床特征及对治疗结果的影响
Drug Alcohol Depend. 2009 Jan 1;99(1-3):248-60. doi: 10.1016/j.drugalcdep.2008.08.010. Epub 2008 Nov 5.
8
Riluzole in the treatment of mood and anxiety disorders.利鲁唑治疗情绪和焦虑障碍
CNS Drugs. 2008;22(9):761-86. doi: 10.2165/00023210-200822090-00004.
9
Capitalizing on extrasynaptic glutamate neurotransmission to treat antipsychotic-resistant symptoms in schizophrenia.利用突触外谷氨酸神经传递来治疗精神分裂症中对抗精神病药物耐药的症状。
Biol Psychiatry. 2008 Sep 1;64(5):358-60. doi: 10.1016/j.biopsych.2008.06.011.
10
Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression.代谢型谷氨酸受体II/III组拮抗剂LY-341495在焦虑和抑郁动物模型中的行为特征
Eur J Pharmacol. 2008 Sep 11;592(1-3):96-102. doi: 10.1016/j.ejphar.2008.06.089. Epub 2008 Jul 2.